Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial Meeting Abstract
| Authors: | Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; Litzow, M.; Lin, T.; Patel, P. A.; Foster, M. C.; Boyiadzis, M.; Collins, R. H.; Vergilio, J. A.; Heerema, N. A.; Rosenberg, L.; Yocum, A. O.; Chen, T.; Druggan, F.; Marcus, S.; Stefanos, M.; Chervin, J.; Shoben, A.; Druker, B. J.; Burd, A.; Byrd, J. C.; Levine, R. L.; Mims, A. S. |
| Abstract Title: | Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205603223 |
| DOI: | 10.1182/blood-2020-143265 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 27 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work